|1.||Tulupov, D A: 1 article (01/2014)|
|2.||Karpova, E P: 1 article (01/2014)|
|3.||Karpycheva, I E: 1 article (01/2014)|
|4.||Biswas, S: 1 article (01/2013)|
|5.||Kirkham, P A: 1 article (01/2013)|
|6.||Hwang, J W: 1 article (01/2013)|
|7.||Rahman, I: 1 article (01/2013)|
|8.||Gramiccioni, Enzo: 1 article (11/2004)|
|9.||Carpagnano, Giovanna E: 1 article (11/2004)|
|10.||Di Gioia, Giuseppe: 1 article (11/2004)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
09/01/2001 - "Carbocysteine lysine salt monohydrate (CLS) is a mucoactive drug effective in the treatment of bronchopulmonary diseases characterized by mucus alterations, including COPD. "
11/28/2004 - "Moreover, we showed an anti-inflammatory and antioxidant effect of short-term administration of SCMC-Lys in COPD, suggesting the importance of a further placebo-controlled study that should evaluate the effects of this drug."
11/28/2004 - "COPD patients treated with SCMC-Lys showed a marked reduction of exhaled 8-isoprostane and Interleukine-6 (8.9+/-1.5 and 4.6+/-0.8 pg/ml, p<0.0001). "
11/28/2004 - "Furthermore, we investigated the anti-inflammatory and antioxidant effects of 6 months treatment with carbocysteine lysine salt monohydrate (SCMC-Lys) in COPD. "
11/28/2004 - "Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys)."
01/01/1990 - "Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis."
01/01/1990 - "The rheological behavior and clearance of bronchial mucus samples collected by protected expectoration from 24 out-patients with simple chronic bronchitis were investigated before, at the end of a short period of treatment (4 days) with a single oral dose of 2.7 g (sachet) of carbocysteine-lysine (evening meal), and on the 4th and 8th days after the end of treatment versus placebo. "
01/01/1982 - "A mass fragmentographic technique was used to study the pharmacokinetic behavior of SCMC-Lys in patients with acute exacerbations of chronic bronchitis and with dense expectoration. "
01/01/1982 - "Pharmacokinetic behavior of S-carboxymethylcysteine-Lys in patients with chronic bronchitis."
01/01/1996 - "It is concluded that continuous administration of SCMC-Lys throughout the winter season is effective in preventing acute exacerbations in patients with chronic obstructive bronchitis and it is well tolerated."
01/01/1996 - "Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial."
01/01/1996 - "The efficacy and safety of carbocysteine lysine salt monohydrate (SCMC-Lys) in the prevention of acute exacerbations associated with chronic obstructive bronchitis were evaluated in a multicenter double-blind, placebo-controlled, parallel group trial in 662 outpatients. "
01/01/2014 - "It was shown that the use of fluifort (carbocysteine lysine salt) for the treatment of exudative otitis media in the children presenting with chronic adenoiditis is a more effective approach in comparison with the expectant management. "
01/01/2014 - "It is concluded that the application of carbocysteine lysine salt in combination with the mometasone furoate nasal spray ensures the rapid elimination of the symptoms of adenoiditis and significantly accelerates the resolution of exudative otitis media compared with the monotherapeutic treatment. "
03/01/1994 - "A controlled double-blind study was carried out vs placebo to evaluate the preventive and therapeutic efficacy of carboxymethylcysteine lysine salt (SCMC-Lys) in 40 non-adenoidectomised children (aged between 6-7 years old) with secretive otitis media and in 30 adult patients with acute inflammatory pathologies of the middle ear. "
|8.||Thioctic Acid (Lipoic Acid)
|9.||Glutathione (Reduced Glutathione)